Latest news with #Mortimer
Yahoo
11-06-2025
- Entertainment
- Yahoo
Emily Mortimer Taps Alison Oliver & Yura Borisov To Lead ‘Dennis,' Her Feature Directorial Debut For A24 & Fruit Tree
EXCLUSIVE: Alison Oliver (Saltburn) and Anora Oscar nominee Yura Borisov have signed on to star in Dennis, a romance marking the feature debut of BAFTA-nominated actress Emily Mortimer, for A24 and Fruit Tree. Written and directed by Mortimer, the film follows a British student (Oliver) and a Russian poet (Borisov) who fall in love in 1990s Moscow. More from Deadline Jonathan Daviss To Star As Snoop Dogg In Universal's Craig Brewer-Directed Biopic Teri Polo, Dylan Walsh & Jamie-Lynn Sigler To Star In Thriller 'The Man Across The Street' Monumental Imagery, Explosive Visuals: Catch Trailer For 'Architecton' That Everyone's Watching The project marks a reunion for A24 and Fruit Tree following their work on two Jesse Eisenberg projects: his forthcoming untitled comedy, starring Julianne Moore and Paul Giamatti, on which we were first to report, and his feature directorial debut, When You Finish Saving the World. Previously, the companies have also collaborated on Jane Schoenbrun's I Saw the TV Glow, as well as The Curse, the Showtime series from Nathan Fielder and Benny Safdie, starring Fielder and Fruit Tree's Emma Stone. Stone, Dave McCary and Ali Herting will produce Dennis through Fruit Tree alongside Mortimer, Alessandro Nivola and Lizzie Nastro Adler for King Bee Productions. Exec producers include Joshua Horsfield for Intake, Viktória Petrányi for Proton Cinema, and Jacob Epstein for Lighthouse. A24 will finance the film and handle its worldwide release. Perhaps best known for a striking supporting turn in Emerald Fennell's Saltburn, Oliver has subsequently reunited with the filmmaker on her Warner Bros adaptation of literary classic Wuthering Heights, which is slated for release on February 13, 2026. Also recently seen in Justin Kurzel's The Order, she'll next be seen starring alongside Mark Ruffalo in HBO's buzzy crime drama Task from Mare of Easttown's Brad Ingelsby. She's represented by Curtis Brown and CAA. Since garnering an Oscar nomination for his turn as Igor in Sean Baker's Anora, Borisov has been tapped to star opposite Andrew Garfield and Monica Barbaro in Artificial, Luca Guadagnino's new AI-themed film for Amazon MGM Studios. He is represented by UTA, ColorCreative, and Gang Tyre Ramer. Breaking out as a filmmaker with The Pursuit of Love, a limited series she wrote and directed for the BBC and Amazon, where she starred alongside Lily James, Andrew Scott, and Dominic West, Mortimer also co-wrote, created, starred in, and showran the HBO series Doll and Em opposite Dolly Wells. Most recently, she co-wrote Jay Kelly, Noah Baumbach's new film for Netflix, where she stars alongside Adam Sandler and George Clooney. As an actress, Mortimer has also worked with top filmmakers including Aaron Sorkin (The Newsroom), Martin Scorsese (Shutter Island, Hugo), Woody Allen (Match Point), Rob Marshall (Mary Poppins), and Craig Gillespie (Lars and the Real Girl), among others. She is represented by UTA, Tavistock Wood, Lighthouse Management & Media, and Sloane Offer Weber & Dern. Best of Deadline 2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More Men of Steel: Every Actor Who Has Played Superman - Photo Gallery 'Michael' Cast: Who's Who In The Michael Jackson Biopic
The Spinoff
09-06-2025
- Entertainment
- The Spinoff
Review: Wrest is too much show
Sam Brooks reviews the new show from Red Leap, a visually stunning mix of theatre and dance. A mundane breakfast, repeated ad nauseam. A coat check in a club. A bloody operating table. A woman pulled in two in a moment at a bus stop. These are images that show up in Red Leap's new show, Wrest, a hybrid of theatre and dance exploring early motherhood. These are also the images that have lingered with me long after the show. They aren't necessarily the images that you might associate with the setting of Wrest, which is set in a neo-noir world that feels closer to Cyberpunk 2077 or Deus Ex than the modern day. They also aren't the images you would associate with the actual narrative of Wrest, which follows a woman – or really, two women, played by Shavorn Mortimer and Ariāna Osborne – literally and sometimes metaphorically finding themselves. Wrest is two shows in one, and too often, these two shows seem in conflict with each other rather than in conversation. The show about motherhood is moving, with a vibrant physicality. The neo-noir mystery allows the show to play inside a rich, familiar, canvas. Too often, however, the mystery is put on pause to develop a visual language, which makes the sequences where the mystery takes centre stage feel perfunctory and even explanatory, rather than evocative. Neither is bad, although I prefer the show about motherhood to the mystery, but they seldom feel connected to each other. The best thing about a Red Leap show is that they demand a lot of the artists they work with, and the artists – on and offstage – absolutely rise to the occasion. While the neo-noir setting lends itself to impressive imagery and an undeniable style, it distracts from the themes of motherhood and identity that Wrest is clearly more interested in exploring. It's not necessarily a question of genre – noir is a broad church of interrogations into various human conditions – but of balance. As the leads, Mortimer and Osborne nail two sides of the same coin. They match each other's physicality and vocal musicality – even though the show has scant dialogue – without being exact mirrors of each other. Mortimer wrangles with the show's centrepiece adeptly, and it's a moment that risks becoming the show's thematic statement just in case the audience have missed it, but she grounds it in an aching humanity that makes the preceding 75 minutes feel worth it, even cohesive. The ensemble is, as is usual for Red Leap, excellent, with Shadon Meredith's specific character work being especially impressive; he moves like a dancer, not like an actor working with choreography. Red Leap is also a company that never fails to deliver, visually and aurally. It goes, then, that the production design, courtesy of Rachel Marlow at Filament 11, is world-class. Sets that would be centrepieces in other productions seem to pop out of nowhere, and disappear just as quickly. A full nightclub is simply (to the audience) spun into focus and then spun out of focus. It is seamless, and impressive. It's in the design that the two shows sitting inside Wrest feel like they actually could belong together. The coldness, even the meaninglessness of the neo-noir world that the two women inhabit, is a rich palette for the lack of direction the characters feel. Where the show really reaches out and grabs you is in the body horror moments – amped up by Eden Mulholland's haunting score – a reminder that some of the most seemingly natural and normal things that a human might go through can be the most absolutely horrific when viewed from afar, or examined from a different direction. The images are so beautiful, so specific, and so rich, but they are so unsupported by the narrative that they end up feeling less like pieces of live performance and movement and more like paintings in a gallery. The designers are working at the height of their ability here, but the story is too generic, and too confusing, that it ends up forming its own kind of fourth wall, placing the audience at a remove when we should be invested. It also doesn't help that the show is very light on dialogue in a genre that is famous for its intricate, musical patter. Noir is the rare genre that can get away with the audience walking away not understanding everything that happened, and dance is an artform that lingers in the same lack of comprehension, but it doesn't feel intentional here. As complaints go, 'too much show' is not the worst one. There is so much at play in Wrest that the genuinely moving, and distressing, exploration of motherhood is hidden. There's so much good in this show, but it's not necessarily the kind of good that fits on the same stage. I'd love to see Red Leap tackle a neo-noir, and play with this cinematic language more onstage. I'd also love to see them continue to explore this thematic territory, I could see a thousand shows about motherhood and still want to see more. In this case, however, I found myself wanting to – apologies – wrest Wrest from itself.
Scottish Sun
19-05-2025
- Entertainment
- Scottish Sun
BBC schedule shake up as string of hit shows taken off air this week
Fan favourite shows will disappear off the TV guide this week gone missing BBC schedule shake up as string of hit shows taken off air this week Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A SCHEDULE shake up on BBC2 this week will see a string of hit shows taken off air. A number of viewers' favourite programmes have been cancelled. Sign up for the Entertainment newsletter Sign up 1 King Charles with David Beckham at the Chelsea Flower Show on Monday Credit: Reuters It's to make way for the coverage of the Chelsea Flower Show which airs every night at 8pm. That means Only Connect, Digging for Britain and Mortimer and Whitehouse: Gone Fishing will all be off air. RHS Chelsea Flower Show is the pinnacle of the gardening calendar, from Sunday, May 18 through to May 25. It is hailed as a celebration of horticultural excellence, sustainability, and creative garden design. This year's coverage features an all-star presenting line-up with some exciting new additions. From Monday to Friday on BBC One and iPlayer from 2pm, Nicki Chapman and Angellica Bell offer practical take-home gardening tips. Every evening on BBC2 and iPlayer from 8pm, Monty Don, Rachel de Thame, and Arit Anderson offer expert insights from Carol Klein, Frances Tophill, and more. Then on May 23 on BBC One and iPlayer from 7:30pm there is a special evening programme hosted by Sophie Raworth and Adam Frost. This weekend, on Saturday May 24 and Sunday May 25 on BBC One, the end-of-week highlights will air with and reflections on BBC Two and iPlayer from 5.25pm. Plus, Radio 2's The Scott Mills Breakfast Show will be live from Chelsea Flower Show on 19 May as he officially unveils the The RHS and BBC Radio 2 Dog Garden live on the station and BBC Sounds.
The Irish Sun
19-05-2025
- Entertainment
- The Irish Sun
BBC schedule shake up as string of hit shows taken off air this week
A SCHEDULE shake up on BBC2 this week will see a string of hit shows taken off air. A number of viewers' favourite programmes have been cancelled. Advertisement 1 King Charles with David Beckham at the Chelsea Flower Show on Monday Credit: Reuters It's to make way for the coverage of the Chelsea Flower Show which airs every night at 8pm. That means Only Connect, Digging for Britain and Mortimer and Whitehouse: Gone Fishing will all be off air. RHS Chelsea Flower Show is the pinnacle of the gardening calendar, from Sunday, May 18 through to May 25. It is hailed as a celebration of horticultural excellence, sustainability, and creative garden design. Advertisement READ MORE ON BBC This year's coverage features an all-star presenting line-up with some exciting new additions. From Monday to Friday on BBC One and iPlayer from 2pm, Nicki Chapman and Angellica Bell offer practical take-home gardening tips. Every evening on BBC2 and iPlayer from 8pm, Monty Don, Rachel de Thame, and Arit Anderson offer expert insights from Carol Klein, Frances Tophill, and more. Then on May 23 on BBC One and iPlayer from 7:30pm there is a special evening programme hosted by Sophie Raworth and Adam Frost. Advertisement Most read in News TV Exclusive This weekend, on Saturday May 24 and Sunday May 25 on BBC One, the end-of-week highlights will air with and reflections on BBC Two and iPlayer from 5.25pm . Plus, Radio 2's The Scott Mills Breakfast Show will be live from Chelsea Flower Show on 19 May as he officially unveils the The RHS and BBC Radio 2 Dog Garden live on the station and BBC Sounds. David Beckham meets with King Charles at Chelsea Flower Show
Hamilton Spectator
12-05-2025
- Business
- Hamilton Spectator
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in Q3 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. 'We continue to make steady progress across our Phase 3 epilepsy program, with patient recruitment into our X-TOLE2 study expected to complete in the next few months, positioning us to report topline results in early 2026. While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study which represents a significant milestone for Xenon, getting us one step closer to a potential first commercial product launch,' said Ian Mortimer, President and Chief Executive Officer of Xenon. 'Outside of epilepsy, we have made tremendous progress across our pipeline, including with azetukalner expansion into neuropsychiatry and significant advancements in our earlier-stage programs. Enrollment in our first Phase 3 MDD study, X-NOVA2, is progressing well and our second MDD study, X-NOVA3, along with our first Phase 3 study in bipolar depression are on track for initiation in the near term. In addition, there is great excitement and momentum across our early-stage programs, with the initiation of a Phase 1 study for our first follow-on Kv7 candidate, XEN1120, that we expect to study in pain, and we anticipate a regulatory filing followed by a Phase 1 study start for our lead Nav1.7 candidate, XEN1701, in the third quarter. It's an incredibly exciting time for Xenon as we advance multiple late-stage development programs and continue to progress multiple early-stage programs, with important milestones expected across our pipeline over the coming year,' stated Mr. Mortimer. Business Highlights and Anticipated Milestones Azetukalner Clinical Development Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD) and bipolar depression (BPD). Epilepsy Programs Neuropsychiatric Programs Early-Stage Pipeline: Next-Generation Ion Channel Modulators Xenon continues to expand its portfolio by leveraging its extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025. Partnered Program First Quarter Financial Results Conference Call Information Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its first quarter 2025 results. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 5532604. About Azetukalner Phase 3 Epilepsy Program Xenon's Phase 3 epilepsy program includes three Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an OLE study for up to three years. About Azetukalner Phase 3 MDD Program Xenon's Phase 3 MDD program includes three multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients with moderate-to-severe major depressive disorder (MDD) per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an OLE study for up to 12 months. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical trials of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators' product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@ For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@ XENON PHARMACEUTICALS INC. Condensed Consolidated Balance Sheets (Expressed in thousands of U.S. dollars) XENON PHARMACEUTICALS INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Expressed in thousands of U.S. dollars except share and per share amounts)
